TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05674331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction site development technique
Description: The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction site development technique
Description: The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autogenous tooth bone graft
Description: ATB was invented by Kim et al. in 2011. The extracted tooth is grinded and goes throw a sterilization procedure by the manufacturer's recommendation. The graft material can be used immediately for ARP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket seal technique
Description: After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket seal technique
Description: After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket seal technique
Description: After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.
Study: NCT05438017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreem 3 System vs PSG
Description: Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.
Study: NCT06189521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave group
Description: In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound group
Description: In addition to the ten-day of physiotherapy program,In the second group, ten days of ultrasound applied at 1.5 watt/cm2 continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone iontophoresis group
Description: In addition to the ten-day of physiotherapy program, In the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
Study: NCT06318949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: If the patient does not object to participating in the study, a blood sample is taken at each visit (an additional tube may be added to a routine blood sample taken for standard care), or a residual blood sample is reused after routine tests have been performed, and data is collected from the medical record.
Study: NCT06450938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI guidance for finding radiographic features
Description: A secured website was made for the trial in which each student could log in using the assigned number. All the image datasets were uploaded to this website. The students will be randomly assigned to the experiment and control group. Both students were asked to segment the features associated with the quality of root canal treatment and predict the prognosis of treatment while the experiment group had access to AI guidance and the control group didn't.
Study: NCT06436027

Intervention type: DIAGNOSTIC_TEST
Intervention: Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling
Description: Targeted molecular profiling will be performed on formalin-fixed paraffin-embedded (FFPE) endomyocardial biopsies using the NanoString nCounter technology. A consortium-approved consensual targeted panel including 770 genes, developed by the Banff Molecular Diagnostics Working Group (MDWG) will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling
Description: Targeted molecular profiling will be performed on formalin-fixed paraffin-embedded (FFPE) endomyocardial biopsies using the NanoString nCounter technology. A consortium-approved consensual targeted panel including 770 genes, developed by the Banff Molecular Diagnostics Working Group (MDWG) will be used.
Study: NCT05218187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EO End-Effector Gait Trainer
Description: The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Treatment
Description: Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Treatment
Description: Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
Study: NCT04762823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar transcranial direct current stimulation at 4 mA
Description: Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar transcranial direct current stimulation at 4 mA
Description: Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar transcranial direct current stimulation
Description: Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar transcranial direct current stimulation
Description: Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
Study: NCT05334745

Intervention type: OTHER
Group type: OTHER
Intervention: Alvogyl
Description: application of Alvogyl in the palatal wound with stent versus hyaluronic acid application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alvogyl
Description: application of Alvogyl in the palatal wound with stent versus hyaluronic acid application
Study: NCT06025162

Intervention type: DRUG
Intervention: enoxaparin
Description: dose of enoxaparin at 48 hours post-VTE prophylaxis initiation
Study: NCT05496946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head bathing skill
Description: A group of students will practice the head bathing skill in a model with low proximity to reality, while the students in the other group will practice on a healthy individual (Standardized patient) pretending to be patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head bathing skill
Description: A group of students will practice the head bathing skill in a model with low proximity to reality, while the students in the other group will practice on a healthy individual (Standardized patient) pretending to be patient.
Study: NCT06409520

Intervention type: DIAGNOSTIC_TEST
Intervention: thyroid function tests
Description: (TSH, free T4) The normal ranges of thyroid function tests were 0.40-4.99 mIU/L for TSH and 0.7-1.8 ng/dL for free T4. The same testing method will performed on all samples from all patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: thyroid function tests
Description: (TSH, free T4) The normal ranges of thyroid function tests were 0.40-4.99 mIU/L for TSH and 0.7-1.8 ng/dL for free T4. The same testing method will performed on all samples from all patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac enzymes
Description: troponine

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac enzymes
Description: troponine

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram
Study: NCT05293210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.~Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.~Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily).
Study: NCT05740735

Intervention type: OTHER
Intervention: Use of expressive sounds
Description: Use of expressive sounds, that is to say the own first name pronounced by the voice of the relative to generate the P300 and a sound with an approaching character of the subject to generate the MMN.~The investigators will thus be able to compare:~* MMN: present/absent for each modality (neutral vs approaching sounds)~* Wave P3a: latencies and amplitudes for each modality (own first name voice of the near vs unfamiliar).

Intervention type: OTHER
Intervention: Having benefited from a prognostic evaluation by event related potentials (without sound research methods, only neutral sounds)
Description: Retrospective inclusion Have already had an assessment with event related potentials without emotional modalities (VF and similar sounds) as part of their care between April 2022 and December 2022 in intensive care at Cochin hospital.
Study: NCT06082583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: Remote ischemic conditioning conducted by an electric auto-control device will be performed twice a day for 14 days, each session including 5-min ischemia and 5-min reperfusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)
Description: Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)
Description: Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
Study: NCT04984954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MUSK pill
Description: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MUSK pill
Description: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
Study: NCT04513184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Dexamethasone
Description: 6 mg from Day 1 to 10 after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Dexamethasone
Description: 0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.
Study: NCT04831294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol
Description: Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
Study: NCT05216536

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05826938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality technology
Description: Participants who are randomized to group 1 will receive the Virtual Reality glasses on the day of oocyte retrieval in the recovery room. The participant chooses which animation she wants to experience.
Study: NCT05450679

Intervention type: PROCEDURE
Intervention: Cervical Radiofrequency Ablation (RFA)
Description: During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.~During the motor stimulation testing step, the pain physicians performing the procedure will assess the presence or absence of cervical paraspinal muscle twitching by using a standardized grading scale (per radiofrequency electrode: 0 = no twitches observed or palpated; 1 = twitches palpated but not observed; 2 = twitches observed and palpated at 1-2 levels; 3 = twitches observed at \> 2 levels). A total score and a weighted score (total score divided by the number of radiofrequency lesion sites), will be recorded for each patient, and the RFA procedure will be completed per usual practice.~RFAs will be performed in the usual manner and as per standard of care. Providers will not use any new or experimental devices to perform the RFA.
Study: NCT06442319

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma intra-articular injection in patients after anterior cruciate ligament reconstruction

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma intra-articular injection in patients after anterior cruciate ligament reconstruction
Study: NCT04895683

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text message content
Description: Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message content
Description: Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message content
Description: Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
Study: NCT05220384

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person Motivational Interview combined with Self-Management techniques
Description: This is an approximately 30 mins in-person, semi-structured, semi-personalized physical activity focused Motivational Interviewing treatment with self-management techniques. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) During the interactive treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. This in-person therapy at the hospital is followed by two booster sessions via phone at the 1st week post meeting date and 1 month post meeting date.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video-based Motivational Interview combined with Self-Management techniques
Description: This is a series of three videos comprising a structured activity focused Motivational Interviewing treatment with self-management techniques. The videos' thematic follow the semi-structured interview elements to ensure that it is a true sham of the in-person one. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) This first video is going to be watched by adolescents at the hospital. During the interactive video-treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. The second video is going to be sent to the participants via e-mail on the 1st week post meeting date and the third video is on the 1-month post meeting date.
Study: NCT05127629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Description: After tooth extraction, a dental implant is placed immediately.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate implant placement
Description: After tooth extraction, a dental implant is placed immediately.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration
Description: After implant placement, the gap between implant and the buccal bone wall is filled with Bio-oss collagen.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Guided bone regeneration
Description: After implant placement, the gap between implant and the buccal bone wall is filled with Bio-oss collagen.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Wound closure with gelatin sponge
Description: After guided bone regeneration, patient in the control group receive gelatin sponge for wound closure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound closure with collagen matrix
Description: After guided bone regeneration, patient in the control group receive collagen matrix (Mucograft Seal) for wound closure.
Study: NCT06109675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: All mothers in this group will be given 3 nutrition education sessions including detailed informations on Nutrition Therapy in Cystic Fibrosis. In addition to the education sessions, an informational booklet and a high-energy sample recipe booklet will be given.
Study: NCT05880186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute caffeine supplementation
Description: To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute caffeine supplementation
Description: To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.
Study: NCT05519982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Treatment Education Program (STEP-1)
Description: Video conference instruction on behavioral changes to improve sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Video conference instruction on relaxation techniques to improve sleep.
Study: NCT05877924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBL-020 for Injection
Description: NBL-020 for Injection, Q3W, i.v.
Study: NCT05614817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous(SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous(SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous(SC) injection
Study: NCT06326320

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Combined SAPB
Description: Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the supine position. 40 ml of 0.25% bupivacaine will be used in applications.
Study: NCT05309070

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control group will receive a placebo, in unmarked boxes, during two months
Study: NCT06231589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sperm Selection
Description: Sperm selection using physiological intracytoplasmic sperm injection (PICSI dish) or magnetic-activated cell sorting (MACS) for selecting sperm with high-quality, better morphology and lower DNA fragmentation.